Abstract

How Much of a Good Thing? What Duration for Interferon Alfa-2b Adjuvant Therapy?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Current approaches to adjuvant therapy of melanoma
Steinar Aamdal
European Journal of Cancer | VOL. 47
Steinar AamdalSteinar Aamdal
01 Sep 2011
Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review
Sonia Okuyama ... Karl Lewis
Core Evidence | VOL. 5
Sonia Okuyama, et. al. Sonia Okuyama ... Karl Lewis
01 Sep 2010
Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia
Sangeetha Venugopal ... Sanam Loghavi
Blood | VOL. 138
Sangeetha Venugopal, et. al.Sangeetha Venugopal ... Sanam Loghavi
05 Nov 2021
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Uma Rao ... Joseph G Ibrahim
Journal of clinical oncology : official journal of the American Society of Clinical Oncology | VOL. 19
Uma Rao, et. al.Uma Rao ... Joseph G Ibrahim
01 May 2001
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori ... Fabio Ciceri
Journal of Clinical Oncology | VOL. -
Cristina Astrid Tentori, et. al.Cristina Astrid Tentori ... Fabio Ciceri
09 May 2024
Addressing Disability in Cancer Survivors
Rachelle Brick ... Emily S Tonorezos
Journal of Clinical Oncology | VOL. -
Rachelle Brick, et. al.Rachelle Brick ... Emily S Tonorezos
09 May 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
Susanna Hegewisch-Becker ... Niall C Tebbutt
Journal of Clinical Oncology | VOL. -
Susanna Hegewisch-Becker, et. al.Susanna Hegewisch-Becker ... Niall C Tebbutt
09 May 2024
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Yuankai Shi ... Zhengbo Song
Journal of Clinical Oncology | VOL. 42
Yuankai Shi, et. al.Yuankai Shi ... Zhengbo Song
30 Apr 2024
View more papers